Related Experiment Video
Updated: May 9, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
The CCND1 G870A polymorphism and susceptibility to bladder cancer
Jing Li1, Fei Luo, Hongtuan Zhang
1Department of Urology, Tianjin Key Lab of Urology, Second Affiliated Hospital of Tianjin Medical University, Tianjin, China.
Summary
The cyclin D1 (CCND1) G870A polymorphism increases bladder cancer risk, particularly in Asian populations and hospital-based studies. This genetic variation is linked to heightened cancer susceptibility overall.
Area of Science:
- Genetics
- Oncology
- Molecular Epidemiology
Background:
- Conflicting results exist regarding the association between the cyclin D1 (CCND1) G870A polymorphism and bladder cancer risk.
- A comprehensive meta-analysis is needed to clarify this relationship.
Purpose of the Study:
- To systematically review and meta-analyze published studies to assess the association between the CCND1 G870A polymorphism and bladder cancer susceptibility.
Main Methods:
- A systematic literature search was conducted on PubMed and the Cochrane Library for eligible studies.
- Statistical analyses were performed using Review Manager 5.0 and Stata 11.0.
- Meta-analysis included subgroup analyses stratified by race and control source.
Main Results:
- A significant association was found between the CCND1 G870A polymorphism and bladder cancer risk in the overall population under a recessive model (OR=1.21, P=0.04).
- The polymorphism was significantly associated with bladder cancer risk in Asians across multiple genetic models (e.g., OR=1.72, P<0.0001 for homogeneous codominant).
- No significant associations were observed in Caucasians. The association was significant in hospital-based case-control studies (OR=1.31, P=0.03) but not in population-based studies.
Conclusions:
- The CCND1 G870A polymorphism likely contributes to increased bladder cancer susceptibility in the overall population, particularly in Asians and within hospital-based case-control study designs.
- Further research may elucidate the specific mechanisms underlying this association in different ethnic groups and study settings.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...